The rituximab paradox in rheumatoid arthritis: Re-evaluating B-cell depletion depth and the synovial microenvironment

Two decades after B-cell depletion altered the therapeutic landscape of rheumatoid arthritis (RA), a clinical paradox persists. Pharmaceutical engineering has yielded advanced anti-CD20 agents (ocrelizumab, ofatumumab) exhibiting superior depletion kinetics. These molecules have triumphed in multiple sclerosis but have failed to demonstrate superior clinical benefit in RA. Rituximab, the chimeric prototype, retains clinical dominance through dose optimization and biosimilar economics.

Optimizing RA treatment does not mandate near-complete systemic B-cell sterilization. Adequate disruption of pathogenic circuits within the synovial niche-specifically the ABC-FLS interaction-suffices for clinical response. Integrating single-cell transcriptomics with longitudinal data from the REDO trial indicates that "incomplete" depletion preserves a critical safety margin of tissue-resident immunity, mitigating infection risks in susceptible populations.

We outline a bifurcated future paradigm: precision tolerance via disease-activity-guided ultra-low dosing for responsive phenotypes and cellular immune resets (CAR-T therapy) targeting deep tissue reservoirs in highly refractory disease.